Pfizer Ventures could be in line for an exit after AbbVie purchased a buyout option for Parkinson's disease drug developer Mitokinin.
Mitokinin, a US-based neurodegenerative disease drug developer backed by Pfizer, sold an exclusive buyout option to another pharmaceutical firm, AbbVie, on Tuesday. AbbVie made an upfront payment of undisclosed size for the right to acquire Mitokinin once it has completed investigational new drug-enabling studies for its lead asset, a potential therapy for Parkinson’s disease for…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.